ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.307,98
0,80%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,06979
-0,11%
Bitcoin
61.425,50
-0,62%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Travere Therapeutics Inc (TVTX)

  7. Travere Therapeutics Inc (TVTX) News

TVTX

Travere Therapeutics (TVTX)

Travere Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TVTX
DatumZeitQuelleÜberschriftSymbolFirma
14/06/202422h05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TVTXTravere Therapeutics Inc
11/06/202423h00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
15/05/202423h00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
13/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
10/05/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/05/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
09/05/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressNASDAQ:TVTXTravere Therapeutics Inc
08/05/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TVTXTravere Therapeutics Inc
06/05/202422h46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TVTXTravere Therapeutics Inc
06/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
06/05/202422h01GlobeNewswire Inc.Travere Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
29/04/202422h30GlobeNewswire Inc.Travere Therapeutics to Report First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
24/04/202413h05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
24/04/202409h00PR Newswire (Canada)CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
24/04/202409h00PR Newswire (US)CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
04/04/202422h30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalNASDAQ:TVTXTravere Therapeutics Inc
03/04/202422h30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationNASDAQ:TVTXTravere Therapeutics Inc
13/03/202422h00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
11/03/202412h05GlobeNewswire Inc.Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)NASDAQ:TVTXTravere Therapeutics Inc
26/02/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TVTXTravere Therapeutics Inc
23/02/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
23/02/202413h05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
23/02/202408h00PR Newswire (Canada)CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyNASDAQ:TVTXTravere Therapeutics Inc
23/02/202408h00PR Newswire (US)CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyNASDAQ:TVTXTravere Therapeutics Inc
20/02/202414h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TVTXTravere Therapeutics Inc
15/02/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TVTX

Kürzlich von Ihnen besucht

TSXV
HMR
Homerun Resources
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten